22 GHP International Life Sciences Awards 2023 As time goes by, we experience more advancements in the world of biotechnology. This progression means we can live longer, healthier lives that are free from the stresses and pain of illness however, without pioneering biotechnology companies this simply wouldn’t be possible. Enter CSL Seqirus, which creates and delivers life-saving and life-improving therapies with dedication, cutting-edge innovation, and pride. Here we learn more as CSL Seqirus wins its prestigious title in the International Life Sciences Awards 2023. GHP Legacy Award in Biotechnology 2023 SL Seqirus’ parent company, CSL, was absolutely instrumental in the fight against the Spanish Influenza Pandemic in 1918. Today, CSL has three companies under its umbrella: CSL Behring, CSL Seqirus, and CSL Vifor. Together, these companies employ around 30,000 dedicated individuals from around the world. Every one of CSL’s team members value patient-focused work, innovation, integrity, and superior performance. Working with several government bodies, CSL Seqirus acts as a buttress for influenza vaccine pandemic preparedness – which not only gives us peace of mind, but this gives us a plan of action should we need it. With its broad range of vaccines and services for rapid response, we can all rest assured that our lives are in good hands. CSL Seqirus “secures health for us all” by preserving and protecting public health. CSL Seqirus utilises both egg and cell-based technologies within its research and development processes. The business’ very own Emmanuella Dekonor tells us, “We are constantly monitoring surveillance data on viruses circulating in animal reservoirs to ensure that we are prepared to support public health agencies should the need arise. As part of our pandemic preparedness activities, we regularly interact with the World Health Organisation (WHO) and routinely acquire avian influenza strains of concern or pandemic potential to build a library of candidate vaccine viruses (CVVs).” By passing everything through its research and development team, CSL Seqirus is always prepared for what is to come. Emmanuella shares “Each year, influenza causes 3 to 5 million cases of severe illness around the world and about 290,000 to 650,000 respiratory deaths. Our bodies and the influenza virus are in a never-ending race; as our immune system evolves to avoid infection, the virus adapts to evade our immune system.” With this in mind, CSL Seqirus strives to create new ways of dealing with seasonal influenza, which is always adapting itself to infect us, spread, and thrive. “Our vision is a world protected from influenza.” The company has state-of-the-art manufacturing facilities and extensive research and production expertise across three continents, to ensure it is always one step ahead of influenza around the globe. Emmanuella says, “In the UK, our site in Liverpool is a Centre of Excellence for adjuvanted influenza vaccine manufacturing and the UK’s largest vaccine manufacturing facility. It is also one of the largest biotechnology sites in Europe and enables the efficient production of seasonal influenza vaccines for both northern and southern hemispheres.” “Liverpool has been at the centre of global pandemic research and science for many years with extensive expertise in medicine, veterinary science, public health, tropical medicine, and behavioural science. It was also the first city globally to undertake a pilot in citywide asymptomatic COVID-19 testing.” CSL Seqirus’ expertise enables timely reactions to a range of issues with influenza. It works tirelessly to stay ahead of the curve in the industry and, in doing so, its vaccines have changed the world. Of course, none of this could be possible without the hard work, flexibility, and passion of its team members. It does everything within its power to deliver solutions on time, every time – and its track record is spotless. Emmanuella comments, “Our fantastic safety record at our Liverpool site shows how impactful it is when people take pride in what they do and speak up to avoid accidents and look out for each other.” Winning the GHP Legacy Award in Biotechnology 2023, CSL Seqirus has earned itself even more recognition for its invaluable work in the field. We are sure to see it continue to save millions of lives year upon year. Contact: Jasmine Dunkley Company: CSL Seqirus Web Address: www.csl.com/we-are-csl/our-businesses-and-products/csl-seqirus C Jun23274 “Derived from the expression “securing health for all of us,” CSL Seqirus has public health protection at its core. This reflects the promise of our parent company CSL, founded in 1916 to save lives and protect the health of people.” 31 GHP Q2 2023 - - B Apr23683 Subscribe to GHP -Subscribe here www.ghp-news.com/subscribe
RkJQdWJsaXNoZXIy MTUyMDQwMA==